Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia.
Adolescent
Adult
Aged
Aged, 80 and over
Antibody Specificity
Autoantibodies
/ immunology
Autoantigens
/ immunology
Blood Platelets
/ immunology
Female
Humans
Male
Middle Aged
Platelet Glycoprotein GPIIb-IIIa Complex
/ immunology
Platelet Glycoprotein GPIb-IX Complex
/ immunology
Purpura, Thrombocytopenic, Idiopathic
/ drug therapy
Recombinant Proteins
/ immunology
Retrospective Studies
Thrombopoietin
/ immunology
Young Adult
autoantibody specificity
glycoprotein
primary immune thrombocytopenia
rhTPO
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
18
01
2021
accepted:
03
04
2021
pubmed:
17
5
2021
medline:
17
12
2021
entrez:
16
5
2021
Statut:
ppublish
Résumé
This retrospective study aimed to evaluate the relationship between plasma autoantibody species and rhTPO response in adult ITP patients who failed the first-line treatments. Plasma anti-glycoprotein (GP) IIb/IIIa and anti-GPIb/IX autoantibodies were detected in 47·2% and 40·6% of the 123 patients, respectively. Overall response rate to rhTPO treatment in patients without anti-GPIb/IX autoantibodies was significantly higher than patients with anti-GPIb/IX autoantibodies (82·2% vs. 60·0%, P = 0·006). By contrast, no statistical difference in response rate was observed between patients with or without anti-GPIIb/IIIa autoantibodies (74·1% vs. 72·3%, P = 0·819). Therefore, the presence of anti-GPIb/IX autoantibodies might serve as a predictive factor for poor response to rhTPO treatment in ITP.
Substances chimiques
Autoantibodies
0
Autoantigens
0
Platelet Glycoprotein GPIIb-IIIa Complex
0
Platelet Glycoprotein GPIb-IX Complex
0
Recombinant Proteins
0
glycoprotein receptor GPIb-IX
0
Thrombopoietin
9014-42-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
191-194Informations de copyright
© 2021 British Society for Haematology and John Wiley & Sons Ltd.
Références
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-66.
Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112-23.
Zhao YQ, Wang QY, Zhai M, Xu J, Chen XQ, Liu WL, et al. A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura. Zhonghua Nei Ke Za Zhi. 2004;43(8):608-10.
Peng J, Ma SH, Liu J, Hou Y, Liu XM, Niu T, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014;12(4):497-504.
Zeng Q, Zhu L, Tao L, Bao J, Yang M, Simpson EK, et al. Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbalpha antibodies. Am J Hematol. 2012;87(2):206-8.
Feng R, Liu X, Zhao Y, Zhu Y, Peng J, Hou M, et al. GPIIb/IIIa autoantibody predicts better rituximab response in ITP. Br J Haematol. 2018;182(2):305-7.
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-86.
Al-Samkari H, Rosovsky RP, Karp Leaf RS, Smith DB, Goodarzi K, Fogerty AE, et al. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Adv. 2020;4(1):9-18.
He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood. 1994;83(4):1024-32.
Porcelijn L, Huiskes E, Oldert G, Schipperus M, Zwaginga JJ, de Haas M. Detection of platelet autoantibodies to identify immune thrombocytopenia: state of the art. Br J Haematol. 2018;182(3):423-6.
Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102(3):887-95.
Yang L, Wang L, Zhao C-H, Zhu X-J, Hou YU, Jun P, et al. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood. 2010;116(20):4307-16.
Li J, van der Wal DE, Zhu G, Xu M, Yougbare I, Ma LI, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun. 2015;6:7737.
Chen M, Yan R, Zhou K, Li X, Zhang Y, Liu C, et al. Akt-mediated platelet apoptosis and its therapeutic implications in immune thrombocytopenia. Proc Natl Acad Sci USA. 2018;115(45):E10682-E10691.
Quach ME, Dragovich MA, Chen W, Syed AK, Cao W, Liang X, et al. Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets. Blood. 2018;131(7):787-96.